- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA Approves single Dosage injectable for Iron Replacement Therapy
![FDA Approves single Dosage injectable for Iron Replacement Therapy FDA Approves single Dosage injectable for Iron Replacement Therapy](https://medicaldialogues.in/h-upload/2021/05/08/750x450_152596-injectafer.webp)
The U.S. Food and Drug Administration (FDA) has recently approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have an intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD). In the updated supplemental New Drug Application (sNDA) for Injectafer®, the experts stated, "--For patients weighing 50 kg or more, Injectafer 15 mg/kg body weight up to a maximum of 1,000 mg intravenously may be administered as a single dose treatment course."
Injectafer was previously approved by the FDA in 2013 with a dosage regimen of 750 mg IV in 2 doses separated by at least 7 days in patients weighing at least 50kg for a total cumulative dose of 1500 mg. The recent updation was based on the 2 randomized, open-label, controlled clinical trials that evaluated the safety and tolerability of Injectafer as a single dose treatment course administered as 15mg/kg to a maximum of 1000 mg in patients weighing at least 50kg.
Linda Mundy, Chief Medical Officer at American Regent, Inc. said, "We are pleased to build on the proven, mainstay Injectafer 1500 mg two-dose course of treatment with the approval of this new 1000 mg single dose option". She further added, "More than 1.7 million patients have been treated with Injectafer in the U.S. and healthcare providers now have an additional dosing option for adult patients with IDA who may not be appropriate for oral iron or who have non-dialysis dependent CKD."
Injectafer® (ferric carboxymaltose injection) is an iron replacement product for the treatment of iron deficiency anemia (IDA) in adult patients who have an intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease. Injectafer® is the most studied IV iron therapy with more than 40 clinical trials with >8800 patients treated worldwide. It is, so far, approved in 83 countries since its initial EU approval in 2007.
Daiichi Sankyo, Inc. anticipates the single 1000 mg dose option of Injectafer will be available in the coming weeks.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751